James Case
As seen in:
MSN,
MSN UK,
Nature,
PNAS,
Taylor & Francis Online,
Science Magazine,
BioRxiv,
Publimetro (Chile),
Cell Host & Microbe,
Cell Press
and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by James Case
Who could replace Michael Carrick if he is sacked by Manchester United?
Michael Carrick's position at Manchester United is under serious threat after a poor start to the season, which plumbed to new depths on Wednesday night when the club were trounced 4-1 by Como. Here Telegraph Sport looks at some of the candidates who could replace Carrick if he is sacked and analyses the case for and against and their suitability for the role.
Who could replace Michael Carrick if he is sacked by Manchester United?
Michael Carrick's position at Manchester United is under serious threat after a poor start to the season which plumbed to new depths on Wednesday night when the club were trounced 4-1 by Como. Here Telegraph Sport looks at some of the candidates who could replace Carrick if he is sacked and analyses the case for and against and their suitability for the role.
12sqM Sharpie British National Championship 2026 at Brancaster Staithe Sailing Club Original
12sqM Sharpie British National Championship 2026 at Brancaster Staithe Sailing Club by James Case 5 Oct 14:36 BST Despite some concerns scheduling the Nationals in October, the weather gods and Brancaster Staithe SC combined to provide the perfect end of season championships. Balmy conditions, sea courses with offshore breezes, and a tight four race schedule with no discards was duly delivered by PRO Bill Andrews and the BSSC team.
Intranasal boosting induces variant-specific responses in SARS-CoV-2 vaccine-imprinted mice
|
Abstract The continued evolution of SARS-CoV-2 variants that evade immunity highlights a need to develop vaccines that elicit variant-specific antibodies and neutralize emerging strains. However, immune imprinting from antecedent SARS-CoV-2 exposure can limit the generation of such antibodies.
By Chieh-Yu Liang, Suzanne M. Scheaffer, James Case, Igor P. Dmitriev, Yuhao Li, Sameer Kumar Malladi, Xinyi Liu, Baoling Ying, Pritesh Desai, Sean Whelan Verified, David Curiel, Ali H Ellebedy, Michael Diamond Verified
|
Nature
Verified
TMPRSS2-mediated coronavirus spike activation and inhibition
|
Abstract The protease TMPRSS2 facilitates coronavirus infections, yet its mechanism of viral glycoprotein recognition remains unclear. Here we show that, following ACE2 engagement of the SARS-CoV-2 spike (S) inducing the early fusion intermediate conformation (E-FIC), TMPRSS2 cleaves the R815 S2′ site and promotes fusogenic conformational changes leading to viral entry.
By Matthew McCallum Verified, James Case, Jack Brown, Young-Jun Park, Jimin Lee, Emmajay Sutherland, Anupriya Aggarwal, Cecily Gibson, Florian A. Lempp, Cameron Stewart Verified, M. Alejandra Tortorici, Jun Siong Low, Daniel Asarnow, Dana Bohan, Exequiel Dellota Jr, Bhavna Chawla, Swagata Kar, Antonio Lanzavecchia, Federica Sallusto, Nicholas Riley, Stuart Turville, Lisa A. Purcell, Michael Diamond Verified, David Veesler, Shilpa Sanapala, Benjamin Merz
|
Nature
Verified
Inside the first 90 days: The state playbook for modern rural health transformation
The $50 billion Rural Health Transformation Program is more than a funding opportunity — it’s a modernization mandate. For states, the first 90 days are a test of whether government can move with the clarity, coordination and the operational discipline required to deliver visible progress across rural communities. This is not business-as-usual public health work.
An intranasal adenoviral-vectored vaccine protects against highly pathogenic avian influenza H5N1 in naive and antigen-experienced animals
Keywords H5N1 influenza virus mucosal vaccine chimpanzee-adenovirus vector Syrian hamster clade 2.3.4.4b pre-existing immunity imprinting Introduction H5N1 avian influenza, a highly pathogenic strain of the influenza A virus (HPAI), poses a threat to the poultry and livestock industry and human public health.
The computationally designed TRI2-2 miniprotein inhibitor protects against multiple SARS-CoV-2 Omicron variants - Communications Biology
|
Abstract The continued evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has compromised neutralizing antibody responses elicited by prior infection or vaccination and abolished the utility of most monoclonal antibody therapeutics. We previously described a computationally-designed, homotrimeric miniprotein inhibitor, designated TRI2-2, that protects mice against pre-Omicron SARS-CoV-2 variants.
By James Case, Young-Jun Park, Daniel Asarnow, M. Alejandra Tortorici, David Baker, Michael Diamond Verified
|
Nature
Verified
12sqM Sharpie British National Championship at Wells Sailing Club
12sqM Sharpie British National Championship at Wells Sailing Club by James Case, event PRO 1 Oct 08:19 PDT Earlier in the year, Wells Sailing Club agreed to host a "low key" championship at the end of the season, due to the 4 yearly cycle of European events being hosted by nearby Brancaster Staithe SC in August. Expectations of around a dozen of the keenest crews participating were re-evaluated when the post Euro enthusiasm had boosted the entry list to 24 Sharpies.
12sqM Sharpie European Championship 2025 at Brancaster Staithe Sailing Club Original
12sqM Sharpie European Championship 2025 at Brancaster Staithe Sailing Club by James Case 17 Aug 23:17 BST The Sharpie class continues to thrive thanks to classic gaff rig and sleek lines, Olympic pedigree, competitive racing, and 94 years of history handed down through many family generations in the Sharpie class, very often in the same boats. Seventy years ago, both my parents crewed Sharpies in the Duke of Connaught week at BSSC, preceding the Olympic trials for Melbourne in 1956.
12sqM Sharpie European Championship at Brancaster Staithe Sailing Club - Preview Original
12sqM Sharpie European Championship at Brancaster Staithe Sailing Club - Preview by James Case, UK class chairman 5 Aug 17:08 BST Sharpies, 94 Not Out! Few dinghy classes can boast such a long and fascinating history as the Sharpie. Designed in 1931 by the German Kruger brothers, they won a design competition for a fast sailing dinghy under 6M, capable of being used for camping.
Improving lung cancer decision-making using a conversation tool (iDECIDE): a stepped wedge pragmatic clinical trial
ABSTRACT Lung cancer is a leading cause of cancer-related mortality. However, few treatment decision-making resources exist. In this study, we evaluate a low literacy lung cancer treatment conversation tool to enhance shared decision-making (SDM). The Improving Decision-Making Encounters in Lung Cancer (iDECIDE) pragmatic, stepped-wedge cluster randomized trial evaluates the effectiveness of a conversation tool for patients with lung cancer.
SARS-CoV-2: The Interplay Between Evolution and Host Immunity
First published as a Review in Advance on December 20, 2024 This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See credit lines of images or other third-party material in this article for license information. Article metrics loading... /content/journals/10.1146/annurev-immunol-083122-043054 Literature Cited 1.
A trivalent mucosal vaccine encoding phylogenetically inferred ancestral RBD sequences confers pan-Sarbecovirus protection in mice
Keywords coronavirus vaccine immunity antibody cellular immunity phylogenetic Sarbecovirus mucosal viral vector T cell Introduction SARS-CoV-2 vaccines have been instrumental in controlling the impact of the pandemic by limiting symptomatic infections, severe disease, hospitalizations, and deaths. However, selective pressures have driven antigenic drift, resulting in immune escape and variant emergence.
Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates - Nature Immunology
Abstract A mucosal route of vaccination could prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication at the site of infection and limit transmission. We compared protection against heterologous XBB.1.16 challenge in nonhuman primates (NHPs) ~5 months following intramuscular boosting with bivalent mRNA encoding WA1 and BA.5 spike proteins or mucosal boosting with a WA1–BA.5 bivalent chimpanzee adenoviral-vectored vaccine delivered by intranasal or aerosol device.
"A Potent and Broad Neutralization of SARS-Cov-2 Variants of Concern by" by Vikas Chonira, Young D Kwon et al.
We report the engineering and selection of two synthetic proteins-FSR16m and FSR22-for the possible treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. FSR16m and FSR22 are trimeric proteins composed of DARPin SR16m or SR22 fused with a T4 foldon.
British 12sqM Sharpie National Championships 2024 at Wells Sailing Club Original
British 12sqM Sharpie National Championships 2024 at Wells Sailing Club by James Case 28 May 18:12 BST The challenge of hosting a Championship over a three day Bank Holiday was duly delivered by Wells SC, however sea courses set 1.5 miles away in Holkham Bay required 0500 alarm calls for the first day's 0700 start time! The volunteer rescue crews cajoled and towed the 17-boat fleet to the course on time, despite a windless launch area.
Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines - Nature
Abstract Immune imprinting is a phenomenon in which prior antigenic experiences influence responses to subsequent infection or vaccination1,2. The effects of immune imprinting on serum antibody responses after boosting with variant-matched SARS-CoV-2 vaccines remain uncertain. Here, we characterized the serum antibody responses after mRNA vaccine boosting of mice and human clinical trial participants.
Computationally restoring the potency of a clinical antibody against Omicron - Nature
Abstract The COVID-19 pandemic underscored the promise of monoclonal antibody-based prophylactic and therapeutic drugs1,2,3 and revealed how quickly viral escape can curtail effective options4,5. When the SARS-CoV-2 Omicron variant emerged in 2021, many antibody drug products lost potency, including Evusheld and its constituent, cilgavimab4,5,6.
Enhancing antibody responses by multivalent antigen display on thymus-independent DNA origami scaffolds - Nature Communications
|
Abstract Protein-based virus-like particles (P-VLPs) are commonly used to spatially organize antigens and enhance humoral immunity through multivalent antigen display. However, P-VLPs are thymus-dependent antigens that are themselves immunogenic and can induce B cell responses that may neutralize the platform.
By Larance Ronsard, Grant A. Knappe, Blake M Hauser, Anna Romanov, James Case, Julie Boucau, Amy K. Barczak, Alejandro B Balazs, Michael Diamond Verified, Aaron Schmidt Verified, Daniel Lingwood
|
Nature
Verified
Neutralization, effector function and immune imprinting of Omicron variants - Nature
|
Abstract Currently circulating SARS-CoV-2 variants have acquired convergent mutations at hot spots in the receptor-binding domain1 (RBD) of the spike protein. The effects of these mutations on viral infection and transmission and the efficacy of vaccines and therapies remains poorly understood. Here we demonstrate that recently emerged BQ.1.1 and XBB.1.5 variants bind host ACE2 with high affinity and promote membrane fusion more efficiently than earlier Omicron variants.
By Luca Piccoli, James Case, Young-Jun Park, Kaitlin R Sprouse, Jessica Bassi, Christian Saliba, Katja Culap, Anushka Rajesh, Jiayi Zhou, Dana Bohan, Alex E. Chen, Florian A. Lempp, Lauriane Kergoat, Florence Larrous, Alessandro Ceschi, Paolo Ferrari, Laura Rosen, Nicholas M. Franko, Cameron Stewart Verified, Helen Y. Chu, Hervé Bourhy, Michael Schmid, Lisa A. Purcell, Gyorgy Snell, Michael Diamond Verified, Davide Corti, Francesco Muoio, Marco Dini, Exequiel Dellota Jr, Olivier Giannini, Jennifer Logue
|
Nature
Verified
Characterization of the SARS-CoV-2 BA.5.5 and BQ.1.1 Omicron Variants in Mice and Hamsters
Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website.
Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants
Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website.
A potent and broad neutralization of SARS-CoV-2 variants of concern by DARPins - Nature Chemical Biology
|
Selection and screening of spike protein-binding DARPin molecules An in-house N3C DARPin library with >109 diversity was used in the phage panning essentially as described previously40. Purified full-length spike protein (BEI NR-52724) and RBD (BEI NR-52306) were biotinylated via EZ-link-sulfo-NHS-LC-biotin (Thermo Fisher Scientific, 21335) and used as target proteins.
By Young D. Kwon, Jason Gorman, James Case, Yaroslav Tsybovsky, Michael Diamond Verified, Peter D. Kwong, Vikas Chonira
|
Nature
Verified
Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains - Nature Communications
Abstract Omicron variant strains encode large numbers of changes in the spike protein compared to historical SARS-CoV-2 isolates. Although in vitro studies have suggested that several monoclonal antibody therapies lose neutralizing activity against Omicron variants, the effects in vivo remain largely unknown.
British 12 square Metre Sharpie National Championship at Wells Sailing Club
British 12 square Metre Sharpie National Championship at Wells Sailing Club by James Case 6 Jun 22:38 PDT The Jubilee weekend provided the best available tides for the championships, unfortunately the wind and weather gods disagreed. Friday provided the best conditions overhead, but the freshening NE breeze made sea conditions increasingly difficult on the day, with wind over tide making challenging conditions for the 18 boats who decided to sail.
Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, Saint Louis, MO, USA
Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting
Highlights • Rationally designed immunogens using glycan engineering and epitope scaffolding. • Immunogens focus murine antibody responses following SARS-2 spike imprinting. • Focusing to the SARS-2 receptor binding motif yields broad, potent neutralization. • Structural characterization of immunogen-elicited mAbs defines conserved epitopes. Summary Eliciting antibodies to surface-exposed viral glycoproteins can generate protective responses that control and prevent future infections.
British Sharpie Championships at Brancaster Staithe Sailing Club
British Sharpie Championships at Brancaster Staithe Sailing Club by James Case 30 Sep 10:25 BST 24-26 September 2021 Top three (l-r) 3rd GBR123, 2nd GBR9, 1st GBR125 during the British Sharpie Championships at Brancaster Staithe © James Case Despite missing a year, Covid affected the expected turnout with our Dutch competitors having to cancel at the last minute. As anticipated in the preview, a reduced field took to the water for Friday's racing.
SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses - Nature
Abstract SARS-CoV-2 mRNA-based vaccines are about 95% effective in preventing COVID-191,2,3,4,5. The dynamics of antibody-secreting plasmablasts and germinal centre B cells induced by these vaccines in humans remain unclear. Here we examined antigen-specific B cell responses in peripheral blood (n = 41) and draining lymph nodes in 14 individuals who had received 2 doses of BNT162b2, an mRNA-based vaccine that encodes the full-length SARS-CoV-2 spike (S) gene1.
Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease
Highlights • SARS-CoV-2 RBD-specific miniproteins confer 100% survival against lethal challenge • Miniproteins prevent SARS-CoV-2-induced lung inflammation and pathology • One miniprotein dose protects when given between D-5 and D+3 relative to infection • Miniproteins inhibit historical, circulating, and emerging SARS-CoV-2 strains SUMMARY Despite the introduction of public health measures and spike protein-based vaccines to mitigate the COVID-19 pandemic, SARS-CoV-2 infections and deaths...
1982: Lebanese Civil War
- Army strength: 780,391 people - Navy strength: 552,996 people - Marine Corps strength: 192,380 people - Air Force strength: 582,845 people - Total strength: 2,108,612 people - Percent of population enlisted: 0.91% Eight hundred U.S. Marines were sent to Beirut in 1982 during the Lebanese Civil War to take out members of the Palestinian Liberation Organization.
Jim Simons’ Road from Mathematics to Market Maven
By James Case The Man Who Solved the Market: How Jim Simons Launched the Quant Revolution. By Gregory Zuckerman. Portfolio/Penguin Random House, New York, NY, November 2019. 384 pages, $30.00. The Man Who Solved the Market: How Jim Simons Launched the Quant Revolution. By Gregory Zuckerman. Courtesy of Portfolio/Penguin Random House. Jim Simons has enjoyed a long and varied career in pure mathematics, code-breaking, and finance.
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly introduced antibody and vaccine countermeasures.
Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion
Significance The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the etiological agent of coronavirus disease-2019 (COVID-19), has swept the world in unprecedented speed. In a few months, SARS-CoV-2 has infected millions of people and caused tens of thousands of deaths. There are no Food and Drug Administration-approved antivirals or vaccines yet available and clinical treatments are limited to supportive therapies that help alleviate the symptoms.
1982: Lebanese Civil War
- Army strength: 780,391 people - Navy strength: 552,996 people - Marine Corps strength: 192,380 people - Air Force strength: 582,845 people - Total strength: 2,108,612 people - Percent of population enlisted: 0.91% Eight hundred U.S. Marines were sent to Beirut in 1982 during the Lebanese Civil War, along with multinational forces, to take out members of the Palestinian Liberation Organization.
De novo design of picomolar SARS-CoV-2 miniprotein inhibitors
Miniproteins against SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is decorated with spikes, and viral entry into cells is initiated when these spikes bind to the host angiotensin-converting enzyme 2 (ACE2) receptor. Many monoclonal antibody therapies in development target the spike proteins. Cao et al. designed small, stable proteins that bind tightly to the spike and block it from binding to ACE2.
A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2
Highlights • Chimpanzee adenoviral vaccines encoding stabilized S induce neutralizing Abs • Chimpanzee adenoviral vaccines protect against SARS-CoV-2 infection and pneumonia • Intranasal vaccine delivery generates robust mucosal B and T cell responses • Intranasal ChAd-SARS-CoV-2 prevents upper and lower respiratory tract infection Summary The coronavirus disease 2019 pandemic has made deployment of an effective vaccine a global health priority.
De novo design of picomolar SARS-CoV-2 miniprotein inhibitors
Abstract Targeting the interaction between the SARS-CoV-2 Spike protein and the human ACE2 receptor is a promising therapeutic strategy. We designed inhibitors using two de novo design approaches. Computer generated scaffolds were either built around an ACE2 helix that interacts with the Spike receptor binding domain (RBD), or docked against the RBD to identify new binding modes, and their amino acid sequences designed to optimize target binding, folding and stability.
De novo design of picomolar SARS-CoV-2 miniprotein inhibitors
You are using an old browser, click here to download PDF
A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection
Wafaa B. Alsoussi, Jackson S. Turner, James B. Case, Haiyan Zhao, Aaron J. Schmitz, Julian Q. Zhou, Rita E. Chen, Tingting Lei, Amena A. Rizk, Katherine M. McIntire, Emma S. Winkler, Julie M. Fox, Natasha M. Kafai, Larissa B. Thackray, Ahmed O. Hassan, Fatima Amanat, Florian Krammer, Corey T. Watson, Steven H. Kleinstein, Daved H. Fremont, Michael S. Diamond and Ali H.
Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice
Highlights • A replicating VSV-SARS-CoV-2 vaccine induces high-titer neutralizing antibodies • Infectious SARS-CoV-2 is undetectable in the lung of vaccinated mice post-challenge • SARS-CoV-2-induced lung inflammation and pathology is decreased in vaccinated mice • Transfer of vaccine-derived immune sera to naïve mice protects against SARS-CoV-2 SUMMARY Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused millions of human infections and an effective vaccine is critical to...
Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2.
Highlights • Vesicular stomatitis virus encoding the SARS-CoV-2 spike replicates to high titers • Virus propagation is enhanced by a truncation in the cytoplasmic tail of the spike • Neutralization can be assessed by BSL2 and BSL3 high-throughput assays • SARS-CoV-2 and VSV-SARS-CoV-2-based neutralization assays correlate Abstract Antibody-based interventions against SARS-CoV-2 could limit morbidity, mortality, and possibly transmission.
A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection
Wafaa B. Alsoussi, Jackson S. Turner, James B. Case, Haiyan Zhao, Aaron J. Schmitz, Julian Q. Zhou, Rita E. Chen, Tingting Lei, Amena A. Rizk, Katherine M. McIntire, Emma S. Winkler, Julie M. Fox, Natasha M. Kafai, Larissa B. Thackray, Ahmed O. Hassan, Fatima Amanat, Florian Krammer, Corey T. Watson, Steven H. Kleinstein, Daved H. Fremont, Michael S. Diamond and Ali H.
A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies
Highlights • Adenovirus transduction of human ACE2 enables SARS-CoV-2 infection of BALB/c mice • High levels of viral RNA and infectious SARS-CoV-2 accumulate in lungs • Mice transduced with human ACE2 develop viral pneumonia after SARS-CoV-2 infection • Neutralizing mAbs protect from SARS-CoV-2-induced lung infection and inflammation Summary Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic with millions of human infections.
A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies
Highlights - Adenovirus transduction of human ACE2 enables SARS-CoV-2 infection of BALB/c mice - High levels of viral RNA and infectious SARS-CoV-2 accumulate in lungs - Mice transduced with human ACE2 develop viral pneumonia after SARS-CoV-2 infection - Neutralizing mAbs protect from SARS-CoV-2 induced lung infection, and inflammation Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic with millions of human infections.
Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals
New Results Seth J. Zost, Pavlo Gilchuk, James Brett Case, Elad Binshtein, Rita E. Chen, Joseph X. Reidy, Andrew Trivette, Rachel S. Nargi, Rachel E. Sutton, Naveenchandra Suryadevara, Lauren E. Williamson, Elaine C. Chen, Taylor Jones, Samuel Day, Luke Myers, Ahmed O. Hassan, Natasha M. Kafai, Emma S. Winkler, Julie M. Fox, James J. Steinhardt, Kuishu Ren, Yueh-Ming Loo, Nicole L. Kallewaard, David R. Martinez, Alexandra Schäfer, Lisa E. Gralinski, Ralph S. Baric, Larissa B. Thackray, Michael S.
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Abstract SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19 pandemic that has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 20201,2. Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies.
Harbour Fence Post Covid-19
Let’s start with a quick look to the future: The cruise ship industry is in very serious trouble. Would you be eager to go on a cruise? Have a read of what The Guardian has to say: https://www.theguardian.com/commentisfree/2020/apr/14/cruise-ships-coronavirus-passengers-future The oil and gas industry is shrinking. Hopefuls in the Newfoundland offshore optimistically argue otherwise, but the writing is on the wall.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with James
Contact James, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack